CRBP · Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals reported a Q1 2026 net loss of $23.0 million, or $(1.23) per share, widening from $17.0 million, or $(1.39) per share, in the prior-year quarter, primarily due to a $4.5 million increase in operating expenses to $24.3 million. Research and development expenses drove the rise, climbing $4.2 million to $19.8 million, reflecting accelerated investment in the company's oncology and obesity pipeline amid key milestones. CEO Yuval Cohen highlighted strong momentum, noting broad FDA alignment on the registrational path for CRB-701, a next-generation Nectin-4 targeting ADC with Fast Track designations for second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer. This positions Corbus to initiate a pivotal HNSCC study this summer, with updated monotherapy data and combination results with Keytruda expected at ASCO 2026 and early 2027, respectively. In obesity, CRB-913, a novel oral CB1 inverse agonist, completed enrollment in the 240-patient CANYON-1 Phase 1b study, with 16-week topline data on track for summer 2026, offering a non-GLP-1 mechanism for weight management. Balance sheet strength supports this trajectory, with $138.2 million in cash, equivalents, and investments as of March 31, 2026, sufficient to fund operations into 2028 under current plans. Investors should monitor upcoming catalysts for potential inflection points in both programs.